GRI Bio (NASDAQ:GRI) Receives Buy Rating from HC Wainwright

GRI Bio (NASDAQ:GRI)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Wednesday, June 11th,Benzinga reports. HC Wainwright also issued estimates for GRI Bio’s Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.78) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.35) EPS.

Separately, Ascendiant Capital Markets cut their price target on shares of GRI Bio from $40.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, May 27th.

GRI Bio Trading Up 2.9%

GRI stock traded up $0.04 during trading on Wednesday, hitting $1.40. 146,892 shares of the stock traded hands, compared to its average volume of 285,994. GRI Bio has a one year low of $1.10 and a one year high of $59.33. The stock has a market cap of $3.00 million, a price-to-earnings ratio of -0.12 and a beta of -1.68. The company has a 50 day simple moving average of $1.50 and a 200 day simple moving average of $6.71.

GRI Bio (NASDAQ:GRI) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($5.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.08) by ($1.72). As a group, analysts predict that GRI Bio will post -3.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GRI Bio

An institutional investor recently raised its position in GRI Bio stock. Geode Capital Management LLC raised its stake in GRI Bio, Inc. (NASDAQ:GRI) by 543.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,182 shares of the company’s stock after acquiring an additional 64,335 shares during the quarter. Geode Capital Management LLC owned about 0.85% of GRI Bio worth $63,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 33.95% of the company’s stock.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.